Treat your heart ailments with longevity-promoting drugs: Carvedilol, a medication used in the treatment of congestive heart failure, left ventricular dysfunction and high blood pressure, may increase life span, via up-regulation of its target gene BubR1, 30/March/2018, 11.06 pm

A sweet way to protect your heart: Trisaccharide-based therapy for Myocardial Infarction: Raffinose, a trisaccharide composed of galactose, glucose, and fructose, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up regulation of PNUTS, 30/March/2018, 10.54 pm
March 30, 2018
Treating viral and bacterial diseases with statins: Statin-based anti-infective therapy: Lovastatin (trade name: Mevacor), a medication used in the treatment of lowering cholesterol, inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15, 30/March/2018,  11.41 pm
March 30, 2018
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:Treat your heart ailments with longevity-promoting drugs: Carvedilol, a medication used in the treatment of congestive heart failure, left ventricular dysfunction and high blood pressure, may increase life span, via up-regulation of its target gene BubR1


From research findings to Therapeutic Opportunity: 

This study suggests, for the first time, that Carvediolby increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (fig. 1).

[easy_payment currency=”USD”]

Figure 1. Carvedilol may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

Figure 2. The chemical structure of Carvedilol.   It  functions as a longevity-promoter by increasing the expression of BuBR1 and other longevity-promoting genes.

 Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing Carvediol or its analogues, either alone or in combination with other drugs, may be used to extend the lifespan of an individual (figs. 2-3).

 


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How carvedilol increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Treat your heart ailments with longevity-promoting drugs: Carvedilol, a medication used in the treatment of congestive heart failure, left ventricular dysfunction and high blood pressure, may increase life span, via up-regulation of its target gene BubR1, 30/March/2018, 11.06 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.